Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — FLORetina ICOOR 12th International Congress on OCT and OCT Angiography 2024
9 slides from Eyepoint's conference presentation, Dec 5, 2024
Slide 1: EYP-1901, a Bioerodible, Sustained-Delivery Intravitreal Insert for nAMD: Preclinical Development to Pivotal Phase 3 Trials
EYP-1901 (vorolanib intravitreal insert), a Bioerodible, Sustained- Delivery Intravitreal Insert for Neovascular Age-Related Macular Degeneration: Preclinical Development to Pivotal Phase 3 Trials Usha Chakravarthy1 Michelle Howard-Sparks,2 Jeff Lynch,2 Monica Roy,2 Ramiro Ribeiro2 1. Queens Univers
Slide 2: Disclosures
Presenter Disclosures Consultant: Alnylam Pharmaceuticals, Annexon Biosciences, Apellis Pharmaceuticals, Aviceda Therapeutics, Exonate, EyePoint Pharmaceuticals, F. Hoffman-La Roche, Isarna Therapeutics, Nanoscope Therapeutics, Ocular Therapeutix, Outlook Therapeutics, Unity Biotechnology Data Monit
Slide 3: Tyrosine Kinase Inhibitors (TKIs) are Pan–VEGFR Inhibitors
Overview - TKIs Tyrosine Kinase Inhibitors (TKIs) are Pan–VEGFR Inhibitors Pathological angiogenesis and vascular instability underlie nAMD TKIs such as vorolanib, sunitiniba, and axitinib are potent pan-VEGFR inhibitors which act intracellularly to prevent pro-angiogenic signaling Vorolanib does no
Slide 4: TKIs Inhibit Angiogenesis More Effectively Than Bevacizumab In Vivo
Preclinical TKIs Inhibit Angiogenesis More Effectively Than Bevacizumab In Vivo Chorioallantoic membrane (CAM) assay1,a Vessels perfusing the sponge Scoring of blood vessel size (VEGFR2 IC50 dose) (VEGFR2 200 x IC50 dose) (VEGFR2 IC50 dose) ✱ ✱✱✱✱ ✱✱ ✱ ✱✱✱✱ 20 20 4 Pan-VEGFR inhibition may be more e
Slide 5: Vorolanib Demonstrated a Neuroprotective Effect in a Mouse Model of Retinal Detachment
Preclinical Vorolanib Demonstrated a Neuroprotective Effect in a Mouse Model of Retinal Detachment Mean change in contrast vision from baselinea 34% reduction in loss of contrast vision vs control (p = 0.0009) ✱✱✱ ns ✱✱✱✱ 18 ✱✱✱✱ 16 Vehicle-treated Mild subretinal fibroplasia Vorolanib is the only T
Slide 6: EYP-1901 (DURAVYU): Vorolanib Intravitreal Insert
Overview – EYP-1901 EYP-1901 (DURAVYUTM): Vorolanib Intravitreal Insert EYP-1901 combines the potent TKI vorolanib with sustained-release drug delivery in an intravitreal insert Bioerodible matrix (Durasert ETM) Delivered in-office via standard IVT injection No delay Reaches target tissues within ho
Slide 7: EYP-1901 Maintained Therapeutic Levels of Vorolanib Through ~9 Months in Rabbit Eyes
Preclinical EYP-1901 Maintained Therapeutic Levels of Vorolanib Through ~9 Months in Rabbit Eyes Vorolanib concentrations following administration of EYP-19011 Single-dose study in rabbits (N=50) 643 µg per eye, bilateral 10000 EYP-1901 maintained therapeutic 1000 concentrations of vorolanib in targ
Slide 8: DAVIO: Phase 1, Single-Injection, Multicenter, Open-Label, Dose-Escalation Trial
DAVIO phase 1 DAVIO: Phase 1, Single-Injection, Multicenter, Open-Label, Dose-Escalation Trial DAVIO enrolled 17 patients with previously-treated nAMD1 EYP-1901 dosing Anti-VEG F per SO Ca Schedu led visit DAVIO demonstrated 440 μg (N = 3) Screen D0/7/14 M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 a favo
Slide 9: Summary
Summary • Vorolanib, a potent pan-VEGFR TKI, inhibits angiogenesis in vivo; and is the only TKI to date to have shown potential neuroprotection in preclinical studies • Non-clinical data suggest potential for extended durability with EYP-1901 • The phase 1 DAVIO trial demonstrated a favorable safety